CORE--Shared Resources Proteomics

描述（由申请人提供）：癌症中心？的蛋白质组学设施支持 癌症中心？通过提供质谱（MS）和表面等离子体共振（SPR）的访问和专业知识，MS对于对蛋白质鉴定、翻译后修饰表征、肽和碳水化合物以及癌细胞蛋白质组的全球研究感兴趣的研究人员来说是一项有价值的技术。SPR提供分子相互作用的实时分析。蛋白质组学设施包括几个质谱仪（MALDI-TOF、ESI-QQQ和Q-TOF）、HPLC、BIAcore 3000仪器和相关分析设备。该设施致力于开发和实施技术，使癌症中心的研究人员能够详细分析特定的蛋白质，或对与癌症生物学相关的多肽子集进行更广泛的基于蛋白质组的筛选。 该设施的具体目标是：1。为癌症中心做贡献？通过提供质谱和表面等离子体共振方面的高质量服务和专业知识，为癌症中心的研究提供支持，并继续培训感兴趣的癌症中心研究人员使用我们的仪器和协议。2.保持在蛋白质组学的技术进步和机会的最前沿，并保持癌症中心的成员在这些技术的最新。3.积极开发新的蛋白质组学技术，并作为癌症中心研究人员的技术开发平台。帮助癌症中心？的新癌症药物发现计划，通过开发小分子的质谱协议。

DESCRIPTION (provided by applicant): The Cancer Center?s Proteomics Facility supports the Cancer Center?s investigators by providing access to and expertise in mass spectrometry (MS) and surface plasmon resonance (SPR). MS is a valuable technology to researchers interested in protein identification, characterization of post-translational modifications, peptides and carbohydrates, as well as global studies of the proteome of cancer cells. SPR provides real-time analysis of molecular interactions. The Proteomics Facility houses several mass spectrometers (MALDI-TOF, ESI-QQQ, and Q-TOF), HPLCs, a BIAcore 3000 instrument, and related analytical equipment. The facility is dedicated to the development and implementation of technology that will allow the Cancer Center investigators to analyze particular proteins on interest in detail or to perform broader proteome-based screens of polypeptide subsets relevant to cancer biology. The Specific Aims for the Facility are: 1. To contribute to the Cancer Center?s research by providing high-quality service and expertise in mass spectrometry and surface plasmon resonance, and to continue to train interested Cancer Center investigators in the use of our instruments and protocols. 2. To stay at the cutting edge of technology advances and opportunities in proteomics, and to keep members of the Cancer Center current in these technologies. 3. To engage in active development of new proteomics techniques, as well as serve as a platform for technology development by Cancer Center investigators. To assist the Cancer Center?s new Cancer Drug Discovery Initiative by developing mass spectrometry protocols for small molecules.